Alzheimer'S Biomarkers

Alzheimer's disease biomarkers are crucial indicators used to detect and monitor the progression of Alzheimer's disease and dementia. These biomarkers include amyloid-beta and tau proteins, which accumulate abnormally in the brain, leading to cognitive decline and memory loss characteristic of the disease. Imaging techniques like PET scans can visualize amyloid plaques, while cerebrospinal fluid tests measure levels of amyloid-beta and tau proteins directly. Biomarkers play a pivotal role in early diagnosis, allowing for interventions to potentially slow disease progression and improve patient outcomes. Ongoing research focuses on refining these biomarkers to enhance accuracy and reliability in diagnosing Alzheimer's disease at its earliest stages, offering hope for better management and treatment strategies in the future.